Jazz Pharmaceuticals plc Website

Jazz Pharmaceuticals plc

NasdaqGS-JAZZ

Company Overview

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

  • Name

    Jazz Pharmaceuticals plc

  • CEO

    Renee D. Gala

  • Website

    www.jazzpharma.com

  • Sector

    Pharmaceuticals

  • Year Founded

    2003

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.

  • Jazz's extensive network of sleep doctors should give the company a competitive edge when marketing its new sleep therapies.

  • Xyrem's historically strong cash generation has allowed the company to make recent acquisitions to help diversify its portfolio.

Bears Say

  • Jazz will face branded competition from Wakix and Lumryz, in addition to generic pressure, which will likely erode Jazz's patient share.

  • It will be more difficult for Jazz to command pricing power with competition from generic Xyrem.

  • The $7.2 billion GW acquisition will be dilutive to both GAAP and non-GAAP adjusted net income in the near term, and it will damp adjusted ROICs.

Source: Morningstar Analysis - Nov 20, 2025

What's happening

Nov 12, 2025 - Dec 12, 2025

Jazz Pharmaceuticals Surges 20.2% Amid Positive Trial Results and Analyst Upgrades

  • Jazz Pharmaceuticals announced positive Phase III trial results for its cancer treatment Ziihera, significantly boosting investor confidence.
  • Deutsche Bank raised its price target for JAZZ from $173 to $210 while maintaining a Buy rating, further enhancing market sentiment.
  • Despite some insider selling that temporarily affected stock prices, JAZZ outperformed both the Health Care sector and the S&P 500.

Over the past month, Jazz Pharmaceuticals (JAZZ) exhibited strong performance with an overall increase of 20.2%. This growth notably surpassed the S&P 500's return of just 0.7%, highlighting significant investor interest in the company’s developments and strategic initiatives. A key driver behind this rise was the announcement on November 17 regarding positive Phase III trial results for Ziihera, which demonstrated substantial improvements in progression-free survival rates among patients with gastroesophageal adenocarcinoma. Following this news, JAZZ shares surged over 20% in premarket trading as analysts recognized the potential impact of these findings on clinical practice.

In addition to favorable trial outcomes, analyst ratings during this period contributed positively to market perception of JAZZ. On November 18, Deutsche Bank increased its price target from $173 to $210 while retaining a Buy rating on the stock. Baird also reaffirmed an Outperform rating after reporting that Ziihera had outperformed Herceptin in clinical evaluations. These endorsements strengthened bullish sentiment among investors and reflected growing confidence in Jazz's pipeline.

Jazz’s visibility was further enhanced through presentations at various medical conferences; comprehensive data about Epidiolex was showcased at the American Epilepsy Society Annual Meeting held from December 5-9. This reinforced Jazz’s commitment to addressing treatment-resistant epilepsies with innovative therapies.

However, there were instances of insider selling that attracted attention and briefly dampened stock prices earlier in December when Chairman Cozadd sold approximately $13.8 million worth of shares prior to announcements about record revenues being made public. Overall, throughout this one-month period marked by significant advancements and strategic communications from management, JAZZ managed to outperform both the Health Care sector by 18.3% and maintain strong momentum against broader market indices like the S&P 500—resulting in an impressive relative performance advantage of over 19% against it.

NasdaqGS:JAZZ